Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, Beijing 100850, China.
Sci China Life Sci. 2013 Mar;56(3):228-33. doi: 10.1007/s11427-013-4447-7. Epub 2013 Mar 23.
As a milestone breakthrough of stem cell and regenerative medicine in recent years, somatic cell reprogramming has opened up new applications of regenerative medicine by breaking through the ethical shackles of embryonic stem cells. However, induced pluripotent stem (iPS) cells are prepared with a complicated protocol that results in a low reprogramming rate. To obtain differentiated target cells, iPS cells and embryonic stem cells still need to be induced using step-by-step procedures. The safety of induced target cells from iPS cells is currently a further concerning matter. More broadly conceived is lineage reprogramming that has been investigated since 1987. Adult stem cell plasticity, which triggered interest in stem cell research at the end of the last century, can also be included in the scope of lineage reprogramming. With the promotion of iPS cell research, lineage reprogramming is now considered as one of the most promising fields in regenerative medicine, will hopefully lead to customized, personalized therapeutic options for patients in the future.
作为近年来干细胞和再生医学的一个里程碑式突破，体细胞重编程通过突破胚胎干细胞的伦理束缚，为再生医学开辟了新的应用途径。然而，诱导多能干细胞（iPS 细胞）的制备需要一个复杂的方案，导致重编程效率很低。为了获得分化的靶细胞，iPS 细胞和胚胎干细胞仍然需要通过逐步诱导来获得。iPS 细胞诱导的靶细胞的安全性目前是一个进一步令人关注的问题。更广泛意义上的谱系重编程自 1987 年以来就一直在研究。在本世纪末引发人们对干细胞研究兴趣的成体干细胞可塑性，也可以包含在谱系重编程的范围内。随着 iPS 细胞研究的推动，谱系重编程现在被认为是再生医学中最有前途的领域之一，有望为未来的患者带来定制化、个性化的治疗选择。
